Please indicate your specialization * Hepatologists Gastroenterologists Endocrinologist General practitioner Other, Please specify: Please indicate your specialization Other, Please specify: What is your preferred method for online learning about recent advances in the management of nonalcoholic steatohepatitis (NASH)? (more than 1 answer possible) * Scientific publications Roundtable/panel discussions by experts in the field Case studies presented by experts in the field Webcasts by experts in the field International congresses highlights Interactive E-learning modules Infographics/visual summaries Other, please specify: What is your preferred method for online learning about recent advances in the management of nonalcoholic steatohepatitis (NASH)? (more than 1 answer possible) Other, please specify: How confident are you in identifying patients at high risk of NASH? * Very confident Confident Reasonably confident, I would like to learn more Not very confident, I should learn more How confident are you in the diagnosis of NASH in your clinical practice? * Very confident Confident Reasonably confident, I would like to learn more Not very confident, I should learn more How familiar are you with the various noninvasive tests and biomarkers for predicting the presence of NASH? * Very familiar, I have a complete understanding of the methods Familiar, I have a basic understanding of the methods I have heard of the methods, but cannot recall it Not familiar How confident are you in the management of NASH in your clinical practice? * Very confident Confident Reasonably confident, I would like to learn more Not very confident, I should learn more How familiar are you with the mode of action of newly emerging treatment options for NASH? * Very familiar, I have a complete understanding of the mode of action Familiar, I have a basic understanding of the mode of action I have heard of the mode of action, but cannot recall it Not familiar How aware are you of the clinical profile of newly emerging treatment options for NASH? * Very aware, I have a complete understanding of newly emerging treatment options Aware, I have a basic understanding of newly emerging treatment options I have heard of newly emerging treatment options, but cannot recall them Not aware How familiar are you with the impact emerging treatments could have on the treatment paradigm of NASH? * Very familiar, I have a complete understanding of the impact emerging treatments could have Familiar, I have a basic understanding of the impact emerging treatments could have I have heard of the impact emerging treatments could have, but cannot recall it Not familiar Obeticholic acid (OCA) is a farnesoid X receptor (FXR) agonist that has been granted accelerated approval for the treatment of primary biliary cholangitis. It is also currently in development for the treatment of NASH. How informed are you about the mode of action of this drug? * Well informed Moderately informed Minimally informed Not informed How informed are you about the efficacy and safety of OCA in the treatment of NASH? * Well informed Moderately informed Minimally informed Not informed How confident are you in identifying eligible patients with NASH to be enrolled in various clinical trials for investigational novel treatments? * Very confident Confident Reasonably confident, but I would like to learn more Not very confident, I should learn more If you are interested in participating in the raffle for a $100 Amazon gift card, please fill out the following: First Name: Last Name: Email: Leave this field blank
